Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Post-traumatic headache is a common sequela of traumatic brain injury and is classified as a secondary headache disorder. In the past 10 years, considerable progress has been made to better understand the clinical features of this disorder, generating momentum to identify effective therapies. Post-traumatic headache is increasingly being recognised as a heterogeneous headache disorder, with patients often classified into subphenotypes that might be more responsive to specific therapies. Such considerations are not accounted for in three iterations of diagnostic criteria published by the International Headache Society. The scarcity of evidence-based approaches has left clinicians to choose therapies on the basis of the primary headache phenotype (eg, migraine and tension-type headache) and that are most compatible with the clinical picture. A concerted effort is needed to address these shortcomings and should include large prospective cohort studies as well as randomised controlled trials. This approach, in turn, will result in better disease characterisation and availability of evidence-based treatment options.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | The Lancet Neurology |
| Vol/bind | 20 |
| Udgave nummer | 6 |
| Sider (fra-til) | 460-469 |
| Antal sider | 10 |
| ISSN | 1474-4422 |
| DOI | |
| Status | Udgivet - jun. 2021 |
Bibliografisk note
Funding Information:
TS reports consultant fees from Eli Lilly Pharmaceuticals, Avanir Pharmaceuticals, and Neuronetrix. AJS reports personal fees from Novartis and Allergan, grants from Novartis, and grants and personal fees from Invex Therapeutics, outside of the submitted work. AIS served on an advisory board for Allergan, currently receives research support from Eli Lilly, and is an associate editor for Cephalalgia and Pain Medicine. HWS has received speaking fees from Novartis and Teva. MJL reports grants and personal fees from Eli Lilly, personal fees from Sanofi-Aventis and YuYu Pharma, and grants from Novartis, Teva, Allergan, and Yuhan, outside of the submitted work. MA is a consultant, speaker, or scientific adviser for AbbVie, Allergan, Amgen, Alder, Biohaven, Eli Lilly, Lundbeck, Novartis, and Teva; primary investigator for Alder, Amgen, Allergan, Eli Lilly, Lundbeck, Novartis, and Teva trials; has no ownership interest and does not own stocks of any pharmaceutical company; serves as an associate editor of Cephalalgia, and associate editor of the Journal of Headache and Pain; and is president of the International Headache Society. All other authors declare no competing interests.
Funding Information:
The views expressed in this Review are those of the authors and do not necessarily reflect the official policy of the Uniformed Services University of the Health Sciences or the US Government. The authors received no specific funding for this Review.
Publisher Copyright:
© 2021 Elsevier Ltd
ID: 285950512